IPP Bureau
Roche’s Elecsys pTau181 becomes first FDA-cleared blood test to rule out Alzheimer’s pathology in primary care
By IPP Bureau - October 14, 2025
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
Vasa Therapeutics secures FDA IND clearance to advance VS-041 into clinical trial for HFpEF
By IPP Bureau - October 14, 2025
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
EY to acquire life science tech firm Aqurance
By IPP Bureau - October 14, 2025
Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
Maverick Simulation installs India’s first 3D anatomage table at Safdarjung Hospital
By IPP Bureau - October 14, 2025
The anatomage table is one of the most advanced 3D real-tissue–based anatomy visualization systems in the world
Biocon gets 1 USFDA observation for Cranbury site
By IPP Bureau - October 14, 2025
The Cranbury facility represents a strategic advancement of the company's operations in the Unted States
Well Pharmacy onboards Datamatics to automate medication record management
By IPP Bureau - October 14, 2025
Datamatics will automate the Medication Administration Record process by integrating its intelligent automation products, TruBot and TruCap+
IPP organizes panel discussion on "challenges and opportunities in Indian pharma sector" in Hyderabad on Oct. 15
By IPP Bureau - October 13, 2025
Speakers are: Ch. A. P. Rameswara Rao, National President, BDMAI; Dr. Paidi Yella Reddy, Founder, President & CEO, Sapala Organics; K. V. Rama Gopal, Site Manager & Executive Director, Clariant India; Dr. K. Nagaiah, Chief Scientist, CSIR - Indian Institute of Chemical Technology, Hyderabad; Dr. Satyanarayana Thirunahari, Senior General Manager - Process Safety & Engineering, Laurus Labs; and Yadavendra Shalgaonkar, Assistant General Manager - Tube Sales, Alleima India
IPP organizes session on "Combating Heat Exchanger Tube Corrosion in Pharma and Chemical Industry" on October 15 at Sheraton Hyderabad Hotel
By IPP Bureau - October 13, 2025
Speakers for the Session are: Venkata Prasad K., Unit Head, Deepak Nitrite; Abhilash Pasham, Associate General Manager - Central Engineering & Projects, Dr. Reddy's Laboratories; C. V. Rajulu, Consultant, Industry; and Jyoti Shankar Jha, Senior Lead Scientist, Alleima India. The moderator for the Session is Pravin Prashant, Executive Editor, Indian Pharma Post
Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025
By IPP Bureau - October 13, 2025
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Relmada therapeutics appoints Dr. Max Kates to propel NDV-01 toward phase 3
By IPP Bureau - October 13, 2025
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Roche to present latest cancer care data at ESMO 2025
By IPP Bureau - October 13, 2025
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
AstraZeneca to unveil breakthrough cancer trial results at ESMO 2025
By IPP Bureau - October 13, 2025
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Cadila launches allergy relief tablet Dlorfast-M
By IPP Bureau - October 13, 2025
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Lupin to present Phase 1 Data on STING agonist at the ESMO Congress 2025
By IPP Bureau - October 13, 2025
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio
By IPP Bureau - October 12, 2025
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
